/AMLX
AMLX Stock - Amylyx Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$12.02+0.84%
+$0.10 (+0.84%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+45.6%upside
Target: $17.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AMLX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.90 – $12.14
TARGET (TP)$17.50
STOP LOSS$11.06
RISK/REWARD1:5.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.33
52W High$16.96
52W Low$2.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $87.37M | $380.79M | $22.23M | N/A | $650,000 |
| Gross Profit | $45.22M | $355.35M | $19.24M | N/A | $-23,944,000 |
| Gross Margin | 51.8% | 93.3% | 86.5% | N/A | -3683.7% |
| Operating Income | $-314,731,000 | $38.80M | $-201,341,000 | $-82,688,000 | $-39,005,000 |
| Net Income | $-301,743,000 | $49.27M | $-198,375,000 | $-87,931,000 | $-42,280,000 |
| Net Margin | -345.4% | 12.9% | -892.4% | N/A | -6504.6% |
| EPS | $-4.43 | $0.73 | $-2.98 | $-1.52 | $-0.79 |
Company Overview
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
13
81%
Hold / Neutral
3
19%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
13 Bullish3 Neutral/Bearish
Price Targets
$22
Average Target
↑ 79.7% Upside
Now
$4
Low
$22
Average
$52
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 10th 2025 | Goldman | Resumed | Buy | $10 |
| June 24th 2025 | Guggenheim | Initiation | Buy | $17 |
| June 17th 2025 | Citigroup | Initiation | Buy | $12 |
| May 30th 2025 | TD Cowen | Initiation | Buy | - |
| April 7th 2025 | Mizuho | Upgrade | Outperform | $7 |
| November 18th 2024 | Robert W. Baird | Upgrade | Outperform | $11← $3 |
| October 23rd 2024 | BofA Securities | Upgrade | Buy | $10← $4.2 |
| March 18th 2024 | Mizuho | Downgrade | Neutral | $4← $32 |
| March 11th 2024 | Leerink Partners | Downgrade | Market Perform | $4← $27 |
| March 11th 2024 | Robert W. Baird | Downgrade | Neutral | $4← $37 |
| March 8th 2024 | Goldman | Downgrade | Neutral | - |
| March 8th 2024 | Evercore ISI | Downgrade | In-line | - |
| January 3rd 2024 | Robert W. Baird | Initiation | Outperform | $37 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $36 |
| July 24th 2023 | Goldman | Upgrade | Buy | $49← $45 |
Earnings History & Surprises
AMLXBeat Rate
38%
Last 16 quarters
Avg Surprise
-45.5%
EPS vs Estimate
Beats / Misses
6/10
Last 12 quarters
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q1 24
-69.6%
$0.07vs$0.23
Q2 24
-291.7%
$-0.46vs$0.24
Q3 24
-92.1%
$-0.73vs$-0.38
Q4 24
-12.8%
$-0.53vs$-0.47
Q1 25
-12.2%
$-0.55vs$-0.49
Q2 25
+6.7%
$-0.42vs$-0.45
Q3 25
-4.5%
$-0.46vs$-0.44
Q4 25
+14.0%
$-0.37vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.43 | $-0.37 | +14.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.44 | $-0.46 | -4.5% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.45 | $-0.42 | +6.7% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $-0.49 | $-0.55 | -12.2% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.47 | $-0.53 | -12.8% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.38 | $-0.73 | -92.1% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.24 | $-0.46 | -291.7% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $0.23 | $0.07 | -69.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $0.44 | $0.30 | -31.8% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $0.10 | $0.31 | +210.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.24 | $0.02 | +108.3% | ✓ BEAT |
Q1 2023 | Mar 13, 2023 | $-0.77 | $-0.65 | +15.6% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.97 | $-0.92 | +5.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.92 | $-0.93 | -1.1% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.75 | $-0.93 | -24.0% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.64 | $-4.15 | -548.4% | ✗ MISS |
Q1 2022 | Jan 10, 2022 | — | $-0.42 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.48 | — | — |
Latest News
Amylyx Pharmaceuticals Announces Early Safety And Tolerability Data From Phase 1 LUMINA Trial Of AMX0114 And results From Ongoing Work Characterizing Biomarkers At 6th International Symposium On ALS/MND
➖ NeutralBenzinga•Dec 5, 2025, 02:04 PM
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $20
📈 PositiveBenzinga•Nov 7, 2025, 07:52 PM
Amylyx Pharma Q3 EPS $(0.37) Beats $(0.45) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:04 PM
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $20
📈 PositiveBenzinga•Oct 17, 2025, 03:21 PM•Also:
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $19
📈 PositiveBenzinga•Oct 16, 2025, 11:30 AM
B of A Securities Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $16
📈 PositiveBenzinga•Oct 3, 2025, 01:06 PM
Goldman Sachs Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $20
📈 PositiveBenzinga•Sep 16, 2025, 04:41 PM
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $25
📈 PositiveBenzinga•Sep 15, 2025, 12:33 PM
Amylyx Pharmaceuticals shares are trading higher. The company announced the pricing of its $175 million underwritten public offering.
📈 PositiveBenzinga•Sep 10, 2025, 04:22 PM
Amylyx Pharmaceuticals Prices $175M Underwritten Public Offering Of 17.5M Shares Of Common Stock At $10 Per Share
➖ NeutralBenzinga•Sep 10, 2025, 06:23 AM
Amylyx Pharmaceuticals Announces An Underwritten Public Offering Of Its Common Stock; Financial Terms Not Disclosed
➖ NeutralBenzinga•Sep 9, 2025, 08:03 PM
Reported Earlier: 'Amylyx's Withdrawn-From-Market Relyvrio Has Failed To Make An Impact On Primary Or Secondary Endpoints In A Rare Neurodegenerative Disease, Prompting The Company To Discontinue The Program' - FierceBiotech
📉 NegativeBenzinga•Aug 28, 2025, 04:09 PM
B of A Securities Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $14
📈 PositiveBenzinga•Aug 28, 2025, 03:47 PM
FDA: Withdrawing Approval Of NDA For Relyvrio For Suspension, 3g/Packet, 1 G/Packet, Held By Amylyx Pharmaceuticals
📉 NegativeBenzinga•Aug 28, 2025, 01:10 PM
Amylyx Pharma To Discontinue ORION Program Of AMX0035 In Adults Living With Progressive Supranuclear Palsy
📉 NegativeBenzinga•Aug 27, 2025, 11:15 AM
Frequently Asked Questions about AMLX
What is AMLX's current stock price?
Amylyx Pharmaceuticals, Inc. (AMLX) is currently trading at $12.02 per share. The stock has moved +0.84% today.
What is the analyst price target for AMLX?
The average analyst price target for AMLX is $17.50, based on 1 analyst.
What sector is Amylyx Pharmaceuticals, Inc. in?
Amylyx Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AMLX's market cap?
Amylyx Pharmaceuticals, Inc. has a market capitalization of $1.00 billion, making it a small-cap company.
Does AMLX pay dividends?
No, Amylyx Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
CVAC
CureVac N.V.
$4.16
Mkt Cap: $0.9B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
Explore stocks similar to AMLX for comparison